Stents are the most common cardiovascular implants used in the treatment of cardiovascular diseases. The coronary stent market exceeded USD 10.31 billion by 2021. That market increased from USD 7.16 billion in 2016, at a compound annual growth rate (CAGR) of 7.6% from 2016 to 2021. Unfortunately, with stent deployment, there is inevitable injury to the endothelium, triggering a cascade of issues such as restenosis and thrombosis. In-stent narrowing (restenosis) often associated with bare metal stents, late stent thrombosis (a blood clot forming in a blood vessel) and inflammatory responses associated with drug-eluting stents all contribute significantly to complications, and even deaths, that can occur with stent implants. The endothelium is the lining of the blood vessels that is a thin layer of endothelial cells and underlying nanofibrillar basement membrane. It modulates vascular tone by release of factors such as nitric oxide. Endomimetics’ bionanomatrix coating provides a pro-healing environment, enhancing healing of the endothelial lining, inhibiting blood clot formation, and limiting restenosis. Endomimetics has evaluated the coating in an established animal model of restenosis. After 28 days in a balloon injury rabbit iliac artery model, commercial bare metal stents (BMS) developed neointimal hyperplasia, and drug-eluting stents (DES) showed incomplete endothelial coverage and inflammation. However, the Endomimetics’ bionanomatrix coated stent exhibited complete re-endothelialization, reduced inflammation, and reduced neointimal hyperplasia.
 |  |